Eli Lilly Merida Biosciences $2.9B Deal Structure Breakdown

Eli Lilly Pays Up to $2.9B for Merida Biosciences' Preclinical Immunology Asset

$2.9 billion. That is the total deal value Eli Lilly put on a preclinical, undisclosed-modality immunology asset from Merida Biosciences, announced August 31, 2026. The collaboration agreement — with an undisclosed upfront payment, undisclosed milestone breakdown, and undisclosed royalty tiers — represents one of the largest preclinical-stage immunology deals of 2026, and it signals that Lilly is willing to pay a significant premium to secure differentiated platform science before clinical proof-of-concept. The Merida Biosciences Eli Lilly deal terms are structured to reward long-term clinical and commercial success, but the headline number alone tells you that Lilly sees franchise-defining potential in whatever Merida is building.

Deal Structure Breakdown

The Merida Biosciences Eli Lilly deal structure leaves many of the critical financial terms undisclosed, which itself is informative. Here is what we know — and what we can infer.

Upfront-to-TDV Ratio: What the Silence Tells You

With neither the upfront nor the milestone split disclosed, we cannot calculate a precise upfront-to-TDV ratio. But context matters. For preclinical immunology collaborations benchmarked through Solidus, the median upfront-to-TDV ratio in 2024–2026 sits between 5% and 12%. Applied to a $2.9B headline, that implies an upfront in the range of $145M–$348M — a wide band, but even the low end is aggressive for a program with no IND filing.

The fact that both parties elected to keep the upfront undisclosed suggests it is large enough to be commercially sensitive for Merida (likely material to a future financing or IPO narrative) and strategically sensitive for Lilly (signaling conviction levels they may not want competitors to price). When a $2.9B deal hides the upfront, the upfront is usually noteworthy.

Milestone Architecture: Risk-Sharing or Conviction Buy?

Without a disclosed milestone split, the best analog is the structure of recent Lilly immunology deals. Lilly's collaborations have historically loaded 60–70% of total deal value into commercial milestones (tiered sales thresholds), 20–30% into regulatory and clinical milestones, and reserved 5–12% for the upfront. If this deal follows that template, Merida is looking at roughly $580M–$870M in clinical and regulatory milestones and $1.7B–$2.0B in commercial milestones. That structure means Lilly is managing downside risk — the bulk of the payout is contingent on blockbuster-level commercial performance. But the sheer TDV at preclinical stage signals that Lilly's internal models project multi-billion-dollar peak sales for this asset, likely across multiple indications in immunology.

Royalties: The Hidden Economics

Royalty terms are undisclosed, but immunology Deal Benchmarks for preclinical collaborations in 2025–2026 show a median royalty range of low-to-mid single digits on the low end, scaling to low double digits at peak tiers. For a deal of this magnitude involving a novel modality, expect Merida negotiated tiered royalties starting in the high single digits and escalating to the low teens — Lilly rarely concedes mid-teens royalties on assets it co-develops from preclinical stage.

Competitive Context — Why Eli Lilly and Why This Asset

Lilly's immunology portfolio has been a deliberate, multi-year buildout. Mirikizumab (Omvoh) anchors their IL-23 franchise in IBD, lebrikizumab addresses atopic dermatitis, and the company has been expanding pipeline depth through selective external deals. But the gaps are clear: Lilly lacks a differentiated next-generation platform in immunology that moves beyond conventional antibody-based approaches. The "other" modality classification on this deal is telling — this is not a standard monoclonal antibody or bispecific. Merida Biosciences appears to offer something architecturally different.

The timing is not accidental. Three competitive dynamics converged in mid-2026:

• AbbVie's immunology dominance is eroding. Humira biosimilar erosion accelerated faster than consensus, and Skyrizi/Rinvoq, while growing, are not unassailable. Lilly sees a window to capture immunology market share with novel mechanisms, not me-too biologics.
• Platform deals are repricing upward. The 2025–2026 wave of AI-driven drug discovery partnerships (across oncology, neuro, and now immunology) has inflated platform valuations. Waiting would have cost Lilly more. The $2.9B TDV, while large, may represent a relative bargain if Merida's platform generates multiple clinical candidates.
• Lilly's balance sheet is flush. GLP-1 revenue from tirzepatide continues to outperform, giving Lilly unmatched BD firepower. When your core franchise generates $30B+ annually, a $2.9B collaboration with a back-loaded milestone structure is a rounding error on the risk side and a franchise play on the upside.

Strategically, this deal fills a specific gap: Lilly needed a preclinical-stage platform collaboration in immunology that could yield multiple INDs across inflammatory and autoimmune indications. Merida appears to deliver that optionality.

What This Means for Similar Assets

If you are a biotech founder or BD lead sitting on a preclinical immunology asset — particularly one classified outside traditional antibody modalities — the Merida Biosciences Eli Lilly deal terms just reset your valuation expectations. Here is how to think about it.

TDV Benchmarks

Prior to this deal, the median TDV for preclinical immunology collaborations announced in 2025–2026 was approximately $800M–$1.2B, based on Ambrosia's dataset of immunology deal benchmarks. Merida's $2.9B is 2.4x–3.6x that median. This is not the new floor — it is an outlier driven by Lilly's strategic urgency and likely by platform-level optionality (multiple indications, multiple candidates). Single-asset, single-indication preclinical deals will not command $2.9B. But if your platform generates a pipeline, not just a molecule, expect TDV conversations to start at $1.5B+ with top-five pharma buyers.

Upfront Expectations

Even without Merida's upfront disclosed, the signal is clear: preclinical immunology upfronts are inflating. In 2024, the median preclinical immunology upfront was $35M–$50M. By mid-2026, deals in the Ambrosia database show that figure creeping toward $75M–$120M for differentiated assets. If your asset has a novel mechanism, strong preclinical data packages, and multi-indication potential, anchor your upfront ask at $100M+ and defend it with this deal as a comparable. Use Solidus to run the precise benchmark against your modality, phase, and therapeutic area.

Royalty Positioning

Royalty expectations for preclinical immunology assets remain in the mid-single to low-double-digit range. The Merida deal is unlikely to have broken that ceiling. Do not overanchor on the TDV and assume you can extract mid-teens royalties at preclinical stage — pharma buyers will push back hard, and rightfully so, given the clinical risk remaining. Target high-single-digit base royalties with escalators tied to net sales thresholds above $2B.

Bottom line: The Merida Biosciences Eli Lilly deal structure tells the market that preclinical immunology platforms with genuine novelty can command headline-grabbing TDVs — but the economic reality for licensors remains back-loaded and milestone-heavy. Structure your term sheet accordingly.

Benchmark Your Deal

Benchmark your own immunology deal against 1,800+ comparable transactions using the Ambrosia calculator. Filter by phase, modality, therapeutic area, and buyer tier to see where your terms sit relative to deals like Merida–Lilly — and identify where you are leaving value on the table.